Cargando…

The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer

OBJECTIVE: In patients who have undergone a potentially curative resection of colorectal cancer, does a ‘second-look’ operation to resect recurrence, prompted by monthly monitoring of carcinoembryonic antigen, confer a survival benefit? DESIGN: A randomised controlled trial recruiting patients from...

Descripción completa

Detalles Bibliográficos
Autores principales: Treasure, Tom, Monson, Kathryn, Fiorentino, Francesca, Russell, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025449/
https://www.ncbi.nlm.nih.gov/pubmed/24823671
http://dx.doi.org/10.1136/bmjopen-2013-004385
_version_ 1782316761635356672
author Treasure, Tom
Monson, Kathryn
Fiorentino, Francesca
Russell, Christopher
author_facet Treasure, Tom
Monson, Kathryn
Fiorentino, Francesca
Russell, Christopher
author_sort Treasure, Tom
collection PubMed
description OBJECTIVE: In patients who have undergone a potentially curative resection of colorectal cancer, does a ‘second-look’ operation to resect recurrence, prompted by monthly monitoring of carcinoembryonic antigen, confer a survival benefit? DESIGN: A randomised controlled trial recruiting patients from 1982 to 1993 was recovered under the Restoring Invisible and Abandoned Trials (RIAT) initiative. SETTING: 58 hospitals in the UK. PARTICIPANTS: From 1982 to 1993, 1447 patients were enrolled. Of these 216 met the criteria for carcinoembryonic antigen (CEA) elevation and were randomised to ‘Aggressive’ or ‘Conventional’ arms. INTERVENTIONS: ‘Second-look’ surgery with intention to remove any recurrence discovered. PRIMARY OUTCOME MEASURE: Survival. RESULTS: By February 1993, 91/108 patients had died in the ‘Aggressive arm’ and 88/108 in the ‘Conventional’ arm (relative risk=1.16, 95% CI 0.87 to 1.37). By 2011 a further 25 randomised patients had died. Kaplan-Meier analysis showed no difference in long-term survival. CONCLUSIONS: The trial was closed in 1993 following a recommendation from the Data Monitoring Committee that it was highly unlikely that any survival advantage would be demonstrated for CEA prompted second-look surgery. This conclusion was confirmed by repeat analysis of survival times after 20 years. TRIAL REGISTRATION NUMBER: ISRCTN76694943.
format Online
Article
Text
id pubmed-4025449
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40254492014-05-21 The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer Treasure, Tom Monson, Kathryn Fiorentino, Francesca Russell, Christopher BMJ Open Surgery OBJECTIVE: In patients who have undergone a potentially curative resection of colorectal cancer, does a ‘second-look’ operation to resect recurrence, prompted by monthly monitoring of carcinoembryonic antigen, confer a survival benefit? DESIGN: A randomised controlled trial recruiting patients from 1982 to 1993 was recovered under the Restoring Invisible and Abandoned Trials (RIAT) initiative. SETTING: 58 hospitals in the UK. PARTICIPANTS: From 1982 to 1993, 1447 patients were enrolled. Of these 216 met the criteria for carcinoembryonic antigen (CEA) elevation and were randomised to ‘Aggressive’ or ‘Conventional’ arms. INTERVENTIONS: ‘Second-look’ surgery with intention to remove any recurrence discovered. PRIMARY OUTCOME MEASURE: Survival. RESULTS: By February 1993, 91/108 patients had died in the ‘Aggressive arm’ and 88/108 in the ‘Conventional’ arm (relative risk=1.16, 95% CI 0.87 to 1.37). By 2011 a further 25 randomised patients had died. Kaplan-Meier analysis showed no difference in long-term survival. CONCLUSIONS: The trial was closed in 1993 following a recommendation from the Data Monitoring Committee that it was highly unlikely that any survival advantage would be demonstrated for CEA prompted second-look surgery. This conclusion was confirmed by repeat analysis of survival times after 20 years. TRIAL REGISTRATION NUMBER: ISRCTN76694943. BMJ Publishing Group 2014-05-07 /pmc/articles/PMC4025449/ /pubmed/24823671 http://dx.doi.org/10.1136/bmjopen-2013-004385 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Surgery
Treasure, Tom
Monson, Kathryn
Fiorentino, Francesca
Russell, Christopher
The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer
title The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer
title_full The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer
title_fullStr The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer
title_full_unstemmed The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer
title_short The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer
title_sort cea second-look trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025449/
https://www.ncbi.nlm.nih.gov/pubmed/24823671
http://dx.doi.org/10.1136/bmjopen-2013-004385
work_keys_str_mv AT treasuretom theceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer
AT monsonkathryn theceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer
AT fiorentinofrancesca theceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer
AT russellchristopher theceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer
AT treasuretom ceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer
AT monsonkathryn ceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer
AT fiorentinofrancesca ceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer
AT russellchristopher ceasecondlooktrialarandomisedcontrolledtrialofcarcinoembryonicantigenpromptedreoperationforrecurrentcolorectalcancer